Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents

Esarte, Silvia Goñi; Juanbeltz, Regina; Zozaya, José Manuel; Úriz, J.; Castilla, Jesús; Herrero, J.I.

doi:10.1016/j.gastrohep.2019.03.017

Cited by 5 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Albeit it could be helpful to perform this research with a bigger sample, we must also consider that we obtained statistically significant results that can be relevant for actual clinical practice. There are also other similar studies published with similar sample sizes [20,39].…”

Section: Discussionmentioning

confidence: 54%

Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection

Murcia

Collado-Romacho

Nievas-Soriano

et al. 2022

JCM

View full text Add to dashboard Cite

Treatment with interferon-free direct-acting antivirals (DAA) has become the gold standard in chronic hepatitis C virus (HCV) infection. Nevertheless, little research about the metabolic impact of achieving sustained virological response (SVR) is available in HCV/HIV co-infected patients. This research aimed to evaluate early anthropometric, lipid and liver parameters changes after achieving SVR 12 weeks after treatment (SVR12). A real-life retrospective descriptive before-after study assessed 128 DAA treatment episodes from 2015 to 2019 in HCV/HIV co-infected patients. Anthropometric parameters (weight, body mass index), lipid profile, genotype (GT) and viral load, liver data (basics laboratory necroinflammatory parameters and transient elastography (TE)) were collected before treatment with DAA (baseline), and when SVR12 was achieved. Significant increases (p < 0.01) were found in the early lipid profile, measured by LDLc (84.6 ± 35.0 vs. 108.6 ± 35.1 mg/dL) and total cholesterol (161.3 ± 41.0 vs. 183.3 ± 41.6 mg/dL). Significant changes (p < 0.05) were found in liver parameters, measured by ALT (58.2 ± 34.0 vs. 22.0 ± 16.0 U/L), bilirubin (0.8 ± 0.6 vs. 0.6 ± 0.5 mg/dL), albumin (4.2 ± 0.4 vs. 4.3 ± 0.3 g/dL) and liver stiffness (LS) (13.7 ± 13.3 vs. 11.8 ± 12.1 kPa). The main conclusions were that the use of DAA has an early negative impact on lipid metabolism. Achieving SVR12 against HCV leads to an early improvement in liver function and LS in HCV/HIV co-infected patients without interference with antiretroviral treatment (ART) and DAA. Short-term close lipid monitoring may be necessary when combining protease inhibitors. HCV-GT-3/HIV co-infected patients might require further close monitoring for residual fibrosis. These findings can be relevant for actual clinical practice.

show abstract

Section: Discussionmentioning

confidence: 54%

Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection

Murcia

Collado-Romacho

Nievas-Soriano

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Studies that enrolled only diabetic patients showed a significant decrease in fasting glucose, HbA1c, and 2 h postprandial blood glucose after viral eradication in more than 65% of patients 76–79 . A greater reduction in fasting glucose and HbA1c was seen at SVR; afterwards, they increased but did not reach the baseline levels 75 .…”

Section: Resultsmentioning

confidence: 99%

Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review

Cespiati,

Coelho Rodrigues,

Santos

et al. 2024

Liver International

View full text Add to dashboard Cite

Background and AimsThe beneficial effect of Hepatitis C virus (HCV) eradication by direct antiviral agents (DAAs) on liver fibrosis is well defined. Despite this, the impact of viral eradication in both hepatic and extra‐hepatic metabolic features is underreached. This systematic review aimed to synthesize the evidence on the impact of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, glucidic impairment, dyslipidaemia, and weight gain.MethodsA systematic search of the existing literature (up to December 2022) identified 97 original studies that fulfilled the inclusion criteria.ResultsWhereas total cholesterol and low‐density lipoprotein (LDL) seem to increase after viral eradication, the cardiovascular damage expressed as carotid plaques and intima‐media thickness seems to improve. Otherwise, the effect on liver steatosis, glucidic homeostasis, and weight seems to be strictly dependent on the presence of baseline metabolic disorders.ConclusionDespite high heterogeneity and relatively short follow‐up of included studies, we can conclude that the presence of metabolic risk factors should be strictly evaluated due to their impact on liver steatosis, glucidic and lipid homeostasis, and on weight gain to better identify patients at risk of liver disease progression despite the virus eradication.

show abstract

Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression

Mendoza,

Tsouka,

Semmler

et al. 2024

Journal of Hepatology

View full text Add to dashboard Cite

Modification of liver fibrosis, glucose and lipid profile after hepatitis C virus clearance with direct-acting antiviral agents

Cited by 5 publications

References 30 publications

Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection

Real-Life Early Anthropometric, Lipid and Liver Changes after Direct-Acting Antiviral Therapy in PLWHIV with HCV Co-Infection

Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review

Metabolic phenotyping of patients with advanced chronic liver disease for better characterization of cirrhosis regression

Contact Info

Product

Resources

About